MAX Power Mining Corp. identified a deep conduit near Lawson 4, enhancing the geological model of Canada's first subsurface Natural Hydrogen system in Saskatchewan. This discovery improves targeting for upcoming completions and highlights potential for large-scale commercialization across 2.5 million acres. The findings support a new primary energy source with testing scheduled to begin in November 2026, aiming to confirm commercial viability. The company also plans further surveys and international engagement to expand exploration and development.
The discovery of a deep conduit near Lawson 4 by MAX Power Mining Corp. provides context for energy sector investors. For readers following energy stocks, here is Pluang's market snapshot as of Nov 02, 2026 20:02 WIB: out of 79 priced US energy stocks, 18 rose and 58 fell. Notable prices include Noble Corporation plc at USD 48.02 with a -2.00% change and a typical hold time of 24 days on Pluang.
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
UroGen Pharma has dosed the first patient in a Phase 1 trial testing UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). The trial aims to evaluate the safety and tolerability of UGN-501 administered directly in...
